GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
U

Uni Pharma Co 6621.TWO · TWD

N/A · Taipei Exchange · 🇹🇼 Taiwan

Compare

12.20

+1.67%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Uni Pharma Co

Its shares trade on Taipei Exchange under the ticker 6621.TWO. It has been listed since 18 August 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 88.4m and a net loss of TWD 40.5m. At that date it held total assets of TWD 275.0m and shareholders' equity of TWD 229.8m.

Unipharma Co., Ltd. engages in the manufacturing, research and development of drugs and medical equipment. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-08-18. The firm's main products include Onko-SureDR-70, for monitoring and marking after Colorectal cancer surgery;Cervi-M, using in detection of DNA methylation for Cervical cancer; EZ Detect, home use fecal occult blood test paper;RFA, cancer treatment medical equipment;Bain inj, a kind of morphine analgesics;Naloxone inj, antidote for morphine drugs overdose;Esmolol inj, ultrashort type B sympathetic nerve blockers;Fomepizole inj, a kind of alcoholic poisoning antidote;and Tambocor tab, a kind of arrhythmia treatment.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
18 Aug 2017

Leadership

Pay as last reported

  • Zheng ChenChairman of the Board
  • Huiling ChenChief Financial Officer, since 2020
  • Liangguang LinGeneral Manager
  • Qiaolei ZhengActing Deputy General Manager
  • Peishan ZhangHead of Finance & Accounting
  • Heying JianIndependent Director
  • Mr. Jialin WangIndependent Director
  • Mingjuan XieIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Uni Pharma Co Ltd develops Onko-SureDR-70 for colorectal cancer surgery monitoring
  • Uni Pharma Co Ltd offers Cervi-M for cervical cancer DNA methylation detection
  • Uni Pharma Co Ltd provides EZ Detect home fecal occult blood test paper

Weaknesses

  • Uni Pharma Co Ltd produces Bain inj as a morphine analgesic
  • Uni Pharma Co Ltd offers Naloxone inj for morphine overdose antidote
  • Uni Pharma Co Ltd has Esmolol inj as ultrashort B sympathetic nerve blockers

Opportunities

  • Uni Pharma Co Ltd markets RFA cancer treatment medical equipment
  • Uni Pharma Co Ltd sells Tambocor tab for arrhythmia treatment
  • Uni Pharma Co Ltd distributes Fomepizole inj for alcohol poisoning antidote

Threats

  • Uni Pharma Co Ltd faces competition in Taipei City market
  • Uni Pharma Co Ltd operates in Taiwan's Health Care sector
  • Uni Pharma Co Ltd is listed on Taipei Stock Exchange

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.